Lecanemab is the first novel treatment for Alzheimer's in more than 20 years Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Lecanemab led to a 44% reduction of biomarker ...

Please provide your email address to receive an email when new articles are posted on . The Infusion-related reactions occurred in roughly one-third of study participants were mild to moderate in ...

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option The BLA is based on data from the ...

The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...

A "boot camp" session at the American Academy of Neurology (AAN) annual meeting focused on the logistical challenges of prescribing lecanemab (Leqembi) for Alzheimer's disease, including how to select ...

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy The sBLA is based on modeling of ...

STOCKHOLM, July 16, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an ...

STOCKHOLM, April 20, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of ...

A Prescription Drug User Fee Act target date of August 31, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...

The researchers found that in all 15 cases, lecanemab-labeled amyloid plaques appeared, indicating potential target engagement. (HealthDay News) — In middle-aged individuals with Down syndrome (DS), ...

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...